Roth Capital Comments on Flora Growth Q1 Earnings

Flora Growth Corp. (NASDAQ:FLGC) – Research analysts at Roth Capital issued their Q1 2026 earnings estimates for shares of Flora Growth in a research note issued on Monday, August 4th. Roth Capital analyst W. Kirk forecasts that the company will post earnings per share of ($45.39) for the quarter. Roth Capital has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Flora Growth’s current full-year earnings is ($0.93) per share. Roth Capital also issued estimates for Flora Growth’s Q2 2026 earnings at ($15.39) EPS, Q3 2026 earnings at $6.54 EPS, Q4 2026 earnings at $12.31 EPS and FY2026 earnings at ($40.39) EPS.

Flora Growth (NASDAQ:FLGC) last released its quarterly earnings data on Friday, August 1st. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Flora Growth had a negative return on equity of 261.57% and a negative net margin of 24.86%. The company had revenue of $14.80 million during the quarter, compared to analysts’ expectations of $11.77 million.

Flora Growth Price Performance

FLGC opened at $19.19 on Wednesday. The stock’s 50 day simple moving average is $25.07 and its 200 day simple moving average is $26.19. The company has a debt-to-equity ratio of 0.50, a current ratio of 0.96 and a quick ratio of 0.67. Flora Growth has a 1 year low of $15.15 and a 1 year high of $82.29. The firm has a market cap of $11.13 million, a price-to-earnings ratio of -0.56 and a beta of 1.97.

Institutional Trading of Flora Growth

An institutional investor recently raised its position in Flora Growth stock. Geode Capital Management LLC boosted its position in shares of Flora Growth Corp. (NASDAQ:FLGC) by 23.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 130,934 shares of the company’s stock after buying an additional 24,713 shares during the quarter. Geode Capital Management LLC owned approximately 0.91% of Flora Growth worth $135,000 as of its most recent filing with the Securities & Exchange Commission. 36.01% of the stock is currently owned by institutional investors.

About Flora Growth

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.